New Therapies for Relapsed Myeloma

Dan Vogl, MD, MSCE, examines new therapies for relapsed myeloma by reviewing recent efficacy, safety and outcomes clinical trials. Agents reviewed include the proteasome inhibitors, the histone deacetylase inhibitors, the monoclonal antibodies and and ibrutinib, vemurafinib and other agents now entering the field.

Related Links

• Clinical Brief: Enrolling Clinical Trials: Umbilical Cord Blood Transplantation vs Haploidentical Transplantation for Patients with Hematological Malignancies
• Dr. Vogl’s Profile